Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Jun 11, 2018 SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced data highlights from five presentations on plazomicin, the Company's lead product c...
May 24, 2018 SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced five upcoming presentations on plazomicin at the American Society for Microbiology (...
May 4, 2018 -- FDA Advisory Committee voted in favor of plazomicin for treatment of adults with complicated urinary tract infections -- -- Conference call today at 8:30 a.m. Eastern Time -- SOUTH SAN FRANCISCO, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a la...
May 2, 2018 SOUTH SAN FRANCISCO, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the U.S. Food and Drug Administration's (FDA) Antimicrobial Drugs Advisory Comm...
May 2, 2018 SOUTH SAN FRANCISCO, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that NASDAQ has halted trading of the Company's common stock. The U.S. Food ...
Apr 26, 2018 -- CARB-X funding to support Achaogen's early-stage aminoglycoside program developing antibiotics for difficult to treat infections that are associated with high mortality -- -- Awarded Up to $2.4 million over approximately 11 months, and potentially up to a total award of $12 m...
Apr 25, 2018 SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its first quarter 2018 financial results on Friday, May 4,...
Apr 23, 2018 -- Study findings support the potential for plazomicin to address difficult-to-treat infections, including those caused by carbapenem-resistant Enterobacteriaceae -- SOUTH SAN FRANCISCO, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company...
Apr 10, 2018 -- Study findings support the potential for plazomicin to address difficult-to-treat infections, including those caused by carbapenem-resistant Enterobacteriaceae -- SOUTH SAN FRANCISCO, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company develo...
Mar 22, 2018 SOUTH SAN FRANCISCO, Calif., March 22, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on March 20, 2018 the compensation committee of the Company's board of ...
Page:
1
... NextLast
= add release to Briefcase